
EVMN
Healthcare · Biotechnology · $315.5M market cap
$7.64-0.38 (-4.8%)Nov 13, 4:00 PM EST
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · -21.5% over 90 days · 30-day revisions 1 up, 0 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 12, 2026 | After the close | -0.82 | -0.85 | -3.7% |
| Aug 6, 2026 | After the close | -0.68 | -0.89 | -30.9% |
| May 8, 2026 | Time not confirmed | -0.85 | -0.64 | +24.7% |
| Mar 5, 2026 | After the close | -0.84 | -1.43 | -70.2% |
| Dec 11, 2025 | After the close | -11.35 | -8.07 | +28.9% |
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The…